New Drug Developments Address Specific Challenges in Autism, With Focus on Subgroups

Targeted Support for Specific Subgroups

The FDA initiated review in September 2025 of leucovorin (folinic acid) for language support in autistic individuals with cerebral folate deficiency (CFD) — a metabolic condition affecting 5-10% of autistic people where folate transport to the brain is impaired (FDA announcement). This marks a narrow but meaningful step toward personalized approaches, as the treatment would only apply to those with confirmed CFD through specialized testing. A clinical trial showed modest language score improvements in some participants, though larger studies are needed to confirm effects (Springer Nature review).

Exploring Experimental Supports

Several investigational compounds are being studied for specific challenges:

Current Medication Landscape Only risperidone and aripiprazole are FDA-approved for autism-related irritability, not core autistic traits.

• Vasopressin nasal spray: Early-stage research at Stanford explores whether this hormone might help some autistic children with social communication preferences, though results remain preliminary and side effects like nasal irritation are common (Stanford Autism Center, Cureus review).
• Suramin: This antiparasitic drug is being tested in a small trial exclusively with male autistic children due to theoretical concerns about hormonal interactions, though critics note this excludes half the autistic population without clear justification (CenterWatch listing).
• Levocarnitine: While animal studies suggested potential mitochondrial support, human trials have not shown significant effects (Nature review).

Current Medication Landscape

Only risperidone and aripiprazole are FDA-approved for autism-related irritability, not core autistic traits. A 2026 systematic review in Nature analyzed over 100 preclinical studies, finding less than 10% translated successfully to humans — highlighting how autism's neurobiological complexity differs from animal models. Researchers emphasize these medications aim to support specific needs like anxiety or epilepsy that some autistic individuals identify as priorities, not to 'treat' autism itself (Frontiers article).

Access and Considerations

For families exploring CFD testing:

• Blood tests for folate receptor autoantibodies can identify CFD, though insurance coverage varies
• Leucovorin side effects may include digestive upset or sleep changes
• Behavioral and communication therapies remain primary supports for most autistic individuals (CORDIS report)